A
1.23
0.00 (0.00%)
| Previous Close | 1.23 |
| Open | 1.25 |
| Volume | 334,412 |
| Avg. Volume (3M) | 396,931 |
| Market Cap | 121,989,312 |
| Price / Sales | 1.98 |
| 52 Weeks Range | |
| Earnings Date | 5 May 2025 - 20 May 2025 |
| Profit Margin | -222.83% |
| Operating Margin (TTM) | -191.82% |
| Diluted EPS (TTM) | -1.62 |
| Quarterly Revenue Growth (YOY) | 0.70% |
| Current Ratio (MRQ) | 3.82 |
| Operating Cash Flow (TTM) | -123.83 M |
| Levered Free Cash Flow (TTM) | -87.93 M |
| Return on Assets (TTM) | -24.13% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | ADC Therapeutics SA | Mixed | Bearish |
AIStockmoo Score
1.9
| Analyst Consensus | 4.0 |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | 1.0 |
| Technical Oscillators | 2.0 |
| Average | 1.88 |
|
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's product candidate includes ZYNLONTA, camidanlumab tesirine, ADCT-602, ADCT-601, ADCT-901, ADCT-701 and ADCT-212. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 20.12% |
| % Held by Institutions | 61.53% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Redmile Group, Llc | 31 Dec 2024 | 15,666,731 |
| Prosight Management, Lp | 31 Dec 2024 | 9,515,000 |
| Orbimed Advisors Llc | 31 Dec 2024 | 5,968,451 |
| Vantage Consulting Group Inc | 31 Dec 2024 | 850,737 |
| Blue Owl Capital Holdings Lp | 31 Dec 2024 | 733,568 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 8.00 (Stephens & Co., 550.41%) | Buy |
| 8.00 (HC Wainwright & Co., 550.41%) | Buy | |
| Median | 8.00 (550.41%) | |
| Low | 7.00 (Guggenheim, 469.11%) | Buy |
| Average | 7.67 (523.58%) | |
| Total | 3 Buy | |
| Avg. Price @ Call | 1.47 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Guggenheim | 31 Mar 2025 | 7.00 (469.11%) | Buy | 1.41 |
| HC Wainwright & Co. | 31 Mar 2025 | 8.00 (550.41%) | Buy | 1.41 |
| Stephens & Co. | 24 Feb 2025 | 8.00 (550.41%) | Buy | 1.60 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |